Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition

(2013) Eric O. Long et al.   Annual Review of Immunology

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy

(2013) Régis T. Costello et al.   IMMUNOLOGY

Natural Cytotoxicity Receptors: Broader Expression Patterns and Functions in Innate and Adaptive Immune Cells

(2013) Kelly Hudspeth et al.   Frontiers in Immunology

Minimal Residual Disease in Myeloma: Are We There Yet?

(2012) Andrew J. Hart et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Use of the anti-inflammatory cytokine interleukin-11 to reverse HIV-1gp120 repression of a natural killer cell line

(2012) Sheena E. Favors et al.   CELLULAR IMMUNOLOGY

Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model

(2012) B. E. Swift et al.   HAEMATOLOGICA

Structural insights into activation of antiviral NK cell responses

(2012) Kathryn A. Finton et al.   IMMUNOLOGICAL REVIEWS

Immune Surveillance Properties of Human NK Cell-Derived Exosomes

(2012) L. Lugini et al.   JOURNAL OF IMMUNOLOGY

NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner

(2012) Andreas Glässner et al.   LABORATORY INVESTIGATION

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

(2012) Caroline Rousseau et al.   TUMOR BIOLOGY

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

(2011) Philipp Baumann et al.   ANTI-CANCER DRUGS

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

(2011) D V Tassev et al.   CANCER GENE THERAPY

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

Inclusion Membrane Proteins of Protochlamydia amoebophila UWE25 Reveal a Conserved Mechanism for Host Cell Interaction among the Chlamydiae

(2010) E. Heinz et al.   JOURNAL OF BACTERIOLOGY

Antibody-maytansinoid conjugates for the treatment of myeloma

(2010) Robert J. Lutz et al.   mAbs

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Impaired NK Cytolytic Activity and Enhanced Tumor Growth in NK Lytic-Associated Molecule-Deficient Mice

(2009) R. G. Hoover et al.   JOURNAL OF IMMUNOLOGY

Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation

(2009) J. A. Olson et al.   JOURNAL OF IMMUNOLOGY

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

(2009) Laurent Boissel et al.   LEUKEMIA RESEARCH

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

(2008) G Maki et al.   LEUKEMIA